- Home
- PCRX vs QSI Comparison
PCRX vs QSI Comparison
Compare PCRX & QSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- QSI
- Stock Information
- Founded
- PCRX 2006
- QSI 2013
- Country
- PCRX United States
- QSI United States
- Employees
- PCRX N/A
- QSI N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- QSI Biotechnology: Pharmaceutical Preparations
- Sector
- PCRX Health Care
- QSI Health Care
- Exchange
- PCRX Nasdaq
- QSI Nasdaq
- Market Cap
- PCRX 1.2B
- QSI 219.8M
- IPO Year
- PCRX 2011
- QSI N/A
- Fundamental
- Price
- PCRX $23.22
- QSI $2.11
- Analyst Decision
- PCRX Buy
- QSI Strong Buy
- Analyst Count
- PCRX 8
- QSI 3
- Target Price
- PCRX $28.38
- QSI $2.38
- AVG Volume (30 Days)
- PCRX 569.8K
- QSI 8.4M
- Earning Date
- PCRX 07-29-2025
- QSI 08-06-2025
- Dividend Yield
- PCRX N/A
- QSI N/A
- EPS Growth
- PCRX N/A
- QSI N/A
- EPS
- PCRX N/A
- QSI N/A
- Revenue
- PCRX $702,772,000.00
- QSI $3,443,000.00
- Revenue This Year
- PCRX $7.54
- QSI $77.57
- Revenue Next Year
- PCRX $10.78
- QSI $251.34
- P/E Ratio
- PCRX N/A
- QSI N/A
- Revenue Growth
- PCRX 3.08
- QSI 167.94
- 52 Week Low
- PCRX $11.16
- QSI $0.61
- 52 Week High
- PCRX $27.64
- QSI $5.77
- Technical
- Relative Strength Index (RSI)
- PCRX 35.42
- QSI 65.03
- Support Level
- PCRX $22.82
- QSI $1.87
- Resistance Level
- PCRX $24.36
- QSI $2.14
- Average True Range (ATR)
- PCRX 0.69
- QSI 0.14
- MACD
- PCRX -0.12
- QSI 0.02
- Stochastic Oscillator
- PCRX 17.09
- QSI 93.65
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About QSI Quantum-Si Incorporated
Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.